The Precision Peptide Company says its needle-free tirzepatide transdermal patch has advanced into formal U.S. testing, according to an October 13 press release from the Vancouver-based company. The patch was first announced as under development on August 19, 2026.

Tirzepatide is the active ingredient in Eli Lilly's Mounjaro and Zepbound. The company's release describes it as a dual GIP/GLP-1 receptor agonist, a synthetic peptide indicated for chronic weight management and given as a once-weekly subcutaneous injection that has to be stored between 2 and 8 degrees Celsius.

The pitch is logistics, not efficacy

What Precision Peptide is selling here is the removal of friction: no needles, no cold chain, no sharps disposal, with room-temperature stability as a stated design goal. The company cites estimates that needle fear affects 20 to 30 percent of young adults and that a significant proportion of patients stop injectable GLP-1 therapy within the first year, and argues a simpler format could support broader adoption.

That is a reasonable hypothesis and an unproven one. Delivering a large peptide across intact skin is the hard part of this problem, and the release says nothing about how the patch is meant to do it.

The numbers in the release are market size, not results

The company reports that existing tirzepatide products generated roughly US$36.5 billion in combined sales in 2025, citing Lilly's own fourth-quarter report. It values the broader GLP-1 market at about US$66 billion in 2025, projected to reach US$185.3 billion by 2033, with injectables accounting for 69.1 percent of the market last year. Gallup polling cited in the release puts GLP-1 use at about 11 percent of U.S. adults as of mid-2026, nearly quadruple the 2024 rate.

Precision Peptide itself notes that this market data is context for its development activities and should not be read as a projection of its revenue or market share. Worth holding onto, because every hard figure in the announcement describes somebody else's sales.

What testing means here

"Formal U.S. testing" is the company's phrase, conducted through its own domestic product-development infrastructure. No trial design, endpoint, participant count or regulatory pathway appears, and the release does not claim FDA approval. The patch is the third product through the same stage-gated route, after a BPC-157 patch that reached a 20,000-unit production order and a TA-1 patch now in testing.

Bottom line

The company says it believes it could be among the first to market with a needle-free tirzepatide patch, while acknowledging others are pursuing needle-free GLP-1 delivery and that there is no assurance it will be first. Until results are published, this is a development milestone announced by the developer, and an update is promised once testing is complete.